Product
NTQ1062
2 clinical trials
2 indications
Indication
HR Positive/HER-2 Negative Breast CancerIndication
CancerClinical trial
A Phase Ib/Ⅱ Study of Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of NTQ1062 Tablets in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase I Study of Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic Effect of NTQ1062 Tablets in Chinese Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-20